40
Participants
Start Date
February 20, 2013
Primary Completion Date
November 11, 2014
Study Completion Date
November 11, 2014
Recombinant Factor VIIa BI (rFVIIa BI)
Administered approximately every 3 hours as an intravenous bolus injection on-demand
Recombinant Factor VIIa BI (rFVIIa BI)
Administered as a single intravenous bolus injection on-demand
Clinic for Hematology of the Clinical Center of Serbia, Belgrade
Tri-Service General Hospital (TSGH), Taipei
Hospital Teresa Herrera Materno Infantil del C.H.U.Carretera del Pasajes/nlaboratorio de hematología, A Coruña
"Health Point Medical Group St Joseph's Children's Hospital", Tampa
University Hospital Virgen del Rocio, Seville
Kyiv City Clinical Hospital #9, City Scientific-Practical Center for Diagnostics and Treatment of Patients with Hemostatic Pathlogies, Kiev
V.K. Gusak Institute of Urgent and Reconstructive Surgery within the Ukrainian National Academy of Medical Sciences, Hematology Department, Donetsk
Hematology Research Center under RAMS (State Institution), Department of Reconstructive Orthopedic Surgery for Hemophilia Patients, Moscow
St. Petersburg City Healthcare Institution Municipal Policlinic # 37, Saint Petersburg
Louis Turcanu Emergency Clinical Children´s Hospital, Timișoara
Kirov Hematology and Blood Transfusion Research Institute under the Federal Medical and Biological Agency of Russia, Kirov
Tokyo Medical University Hospital, Tokyo
Nara Medical University Hospital, Nara
Kracow Medical Center, LLC, Krakow
Institute of Haematology and Transfusion Medicine, Clinic of Haemostatic Disorders and Internal Diseases, Warsaw
"State Institution Institute of Blood Pathology and Transfusion Medicine within the Ukrainian National Academy of Medical Sciences, Hematology Department", Lviv
Baxalta now part of Shire
INDUSTRY